… , particularly, the PERK pathway can be observed … modulation of the PERK pathway results
in potent neuroprotection. Targeting aberrant UPR signalling is the focus of new therapeutic …

… We can conclude that PERK pathway modulation using small molecule drugs is a very
promising therapeutic approach for a wide variety of neurodegenerative diseases. It is surprising …

… provide key insights into the physiology of different cancers, which could see advancements
in treatment through therapeutic modification or modulation of the PERK pathway. Inhibiting …

… therapeutic potential of UPR modulation in vitro and in vivo. We observed that in contrast to
the dogma stating that PERK … UPR pathways with a strong activation of the PERK pathway in …

… These data led to the prediction that pharmacological modulation of the PERK-dependent …
of the PERK-dependent UPR signaling pathways may constitute a novel therapeutic strategy …

… that is selective for PERK activation and hence … to therapeutic modulation of this pathway
in neurodegeneration. To do this, we exploited a separate mechanism for modulating PERK …

… provided strong support of the pathological link between PERK and trisomy 21. Our results
suggest that failure to regulate the PERK pathway is a peculiar characteristic of DS pathology …

… PERK pathway to contribute to the induction of the chemokines CXCL8 and CCL20, thus
revealing a novel mechanism for ER stress-mediated modulation … and therapeutic outcomes. In …

… regulator cyclin D1 and lipid biosynthesis modulator insig1 (insulin inducible gene 1), …
pathways are potential therapeutic targets. In this section, we focus on the contributions of PERK …

… Several inhibitors of the Akt pathway have been developed as therapeutic treatments, some
of which are currently being tested in clinical trials [13]–[16]. One of these inhibitors is the …